Oral Selenium in the treatment of refractory severe Atopic dermatitis: Report of 4 cases

Authors

  • A Koohkan
  • AH Farhoodi
  • AR Ranjbar
  • M Movahedi
  • Z Pourpak
Abstract:

Atopic dermatitis (AD) is a chronic, inflammatory and pruritic skin disease with a prevalence of 10-20%. Recent studies suggested the effect of selenium on immunoregulation in AD. In this study we report 4 cases of atopic dermatitis according to Hafniin and Rajka criteria. Serum selenium levels were increased and serum total IgE were decreased in all patients. These results show that selenium is in the cells, therefore selenium could be a suitable and effective treatment. Further studies are required with increased subjects, different dosages and treatment duration to reach more definite results.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

The efficacy of phototherapy in treatment of resistant Atopic dermatitis

Background: Due to the chronic nature of atopic dermatitis and dependence of most patients to steroids, finding a suitable alternative treatment is important. Objectives: To determine the efficacy of phototherapy in treatment of atopic dermatitis, also to evaluate possible influencing factors in response of patients to psoralen+UVA (PUVA) therapy. Patients and Methods: 13 patients with resistan...

full text

"high doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis "

atopic dermatitis is one of the most common allergic diseases that almost always respond to conventional therapies with topical emollient, topical corticosteroids, systemic antihistamines and allergic abstinence. however few cases of atopic dermatitis with severe course do not respond to conventional therapies and high dose of intravenous immunoglobulin or cyclosporine are recommended for them....

full text

Successful use of ustekinumab therapy in refractory severe atopic dermatitis

AD: atopic dermatitis IL: interleukin Th: T helper cell INTRODUCTION Moderate-to-severe atopic dermatitis (AD) often requires systemic treatments with immunomodulatory drugs. Unfortunately, systemic agents currently used for AD have extensive side effects, and many patients experience suboptimal therapeutic responses. Additionally, many of these treatments, such as cyclosporine A, can only be u...

full text

bath puva in severe and refractory atopic dermatitis

background atopic dermatitis (ad) is a chronic inflammatory skin disease. phototherapy is considered as an effective treatment modality in severe cases. objectives in this study, we proposed to evaluate the efficacy of bath puva (psoralen plus ultraviolet a) in the treatment of severe and atopic dermatitis. patients and methods twenty-eight patients with severe atopic dermatitis were included i...

full text

Omalizumab treatment in severe adult atopic dermatitis.

Atopic dermatitis (AD) is one of the most common chronic skin diseases. Treatment options include lubricants, antihistamines, and corticosteroids in either topical or oral forms. Severe AD is frequently recalcitrant to these medications. We reported three cases of severe AD patients who had elevated of IgE levels and failed to response to several prior medical treatment. After being treated wit...

full text

Detoxification Combining Fasting with Fluid Therapy for Refractory Cases of Severe Atopic Dermatitis

To introduce and determine the clinical benefits of a detoxification program that combines fasting with fluid therapy for refractory cases of severe atopic dermatitis (AD), we performed a retrospective chart review of inpatients with AD from March 2010 to February 2012 at the Department of Ophthalmology, Otorhinolaryngology and Dermatology of Korean Medicine in the Kyung Hee Medical Center. Pat...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 6  issue 2

pages  40- 52

publication date 2003-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023